Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2026-02-26 22:42Financial Data and Indicators - The company reported total revenue of approximately 1,067.91 million yuan, representing a year-on-year increase of 26.18% [1][2] - The net profit attributable to the parent company was approximately 27.87 million yuan, marking a turnaround from a loss to profit compared to the same period last year [1][2] - The net profit attributable to the parent company, excluding non-recurring gains and losses, was approximately -92.50 million yuan [1] Operational Performance and Financial Condition - The company has implemented a development strategy focused on innovation and commercialization, leading to sustained revenue growth from its first quadrivalent meningococcal vaccine, Manhaixin [2] - Cost reduction and efficiency improvement measures have been effectively managed, contributing to enhanced overall profitability [2] - The company received government subsidies and international research funding, which were recognized as non-recurring gains during the reporting period [2] Changes in Key Financial Metrics - Operating profit, total profit, and net profit attributable to the parent company all achieved a turnaround from loss to profit year-on-year [3] - Basic earnings per share and weighted average return on net assets turned positive [3] - The net loss attributable to the parent company, excluding non-recurring gains and losses, narrowed year-on-year due to increased revenue and cost-saving measures [3]